PDT Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $430K | Hold |
2,348
| – | – | 0.03% | 429 |
|
|
2025
Q4 | $413K | Hold |
2,348
| – | – | 0.03% | 446 |
|
|
2025
Q3 | $329K | Sell |
2,348
-29,316
| -93% | -$3.96M | 0.02% | 498 |
|
|
2025
Q2 | $3.98M | Buy |
+31,664
| New | +$3.95M | 0.22% | 153 |
|
|
2025
Q1 | – | Sell |
-39,405
| Closed | -$6.03M | – | 751 |
|
|
2024
Q4 | $6.03M | Buy |
39,405
+22,908
| +139% | +$3.86M | 0.53% | 16 |
|
|
2024
Q3 | $3.2M | Buy |
16,497
+9,997
| +154% | +$2.09M | 0.28% | 101 |
|
|
2024
Q2 | $1.51M | Buy |
+6,500
| New | +$1.41M | 0.14% | 259 |
|
|
2024
Q1 | – | Sell |
-6,125
| Closed | -$1.58M | – | 629 |
|
|
2023
Q4 | $1.58M | Buy |
6,125
+4,525
| +283% | +$1.11M | 0.18% | 197 |
|
|
2023
Q3 | $411K | Buy |
+1,600
| New | +$428K | 0.05% | 439 |
|
|
2023
Q2 | – | Sell |
-3,039
| Closed | -$845K | – | 579 |
|
|
2023
Q1 | $845K | Buy |
+3,039
| New | +$841K | 0.11% | 298 |
|
|
2022
Q4 | – | Sell |
-1,175
| Closed | -$314K | – | 649 |
|
|
2022
Q3 | $314K | Buy |
+1,175
| New | +$250K | 0.05% | 572 |
|
|
2022
Q2 | – | Sell |
-6,544
| Closed | -$1.38M | – | 963 |
|
|
2022
Q1 | $1.38M | Buy |
6,544
+4,097
| +167% | +$891K | 0.12% | 270 |
|
|
2021
Q4 | $587K | Buy |
+2,447
| New | +$629K | 0.04% | 487 |
|
|
2020
Q4 | – | Sell |
-27,513
| Closed | -$7.8M | – | 699 |
|
|
2020
Q3 | $7.8M | Sell |
27,513
-2
| -0% | -$558 | 0.52% | 41 |
|
|
2020
Q2 | $7.36M | Sell |
27,515
-7,107
| -21% | -$2.14M | 0.5% | 66 |
|
|
2020
Q1 | $11M | Buy |
34,622
+2,501
| +8% | +$759K | 0.87% | 8 |
|
|
2019
Q4 | $9.53M | Sell |
32,121
-10,379
| -24% | -$2.88M | 0.59% | 45 |
|
|
2019
Q3 | $9.89M | Hold |
42,500
| – | – | 0.59% | 35 |
|
|
2019
Q2 | $9.94M | Buy |
+42,500
| New | +$9.81M | 0.59% | 42 |
|
|
2018
Q3 | – | Sell |
-39,800
| Closed | -$11.6M | – | 477 |
|
|
2018
Q2 | $11.6M | Hold |
39,800
| – | – | 0.44% | 68 |
|
|
2018
Q1 | $10.9M | Sell |
39,800
-15,500
| -28% | -$4.81M | 0.37% | 85 |
|
|
2017
Q4 | $17.6M | Buy |
55,300
+12,600
| +30% | +$4.04M | 0.51% | 64 |
|
|
2017
Q3 | $13.4M | Sell |
42,700
-6,400
| -13% | -$1.9M | 0.44% | 75 |
|
|
2017
Q2 | $13.3M | Buy |
49,100
+19,600
| +66% | +$5.18M | 0.54% | 45 |
|
|
2017
Q1 | $8.07M | Buy |
29,500
+5,400
| +22% | +$1.53M | 0.42% | 79 |
|
|
2016
Q4 | $6.83M | Sell |
24,100
-14,100
| -37% | -$4.18M | 0.45% | 46 |
|
|
2016
Q3 | $12M | Buy |
38,200
+10,000
| +35% | +$2.96M | 0.7% | 5 |
|
|
2016
Q2 | $6.82M | Buy |
+28,200
| New | +$7.43M | 0.54% | 75 |
|
|
2015
Q4 | – | Sell |
-57,546
| Closed | -$16.8M | – | 458 |
|
|
2015
Q3 | $16.8M | Sell |
57,546
-319
| -0.6% | -$105K | 0.38% | 59 |
|
|
2015
Q2 | $23.4M | Buy |
57,865
+4,630
| +9% | +$1.86M | 0.61% | 21 |
|
|
2015
Q1 | $22.5M | Buy |
53,235
+50,405
| +1,781% | +$19.9M | 0.56% | 20 |
|
|
2014
Q4 | $961K | Sell |
2,830
-78,711
| -97% | -$25.5M | 0.09% | 311 |
|
|
2014
Q3 | $27M | Buy |
81,541
+79,811
| +4,613% | +$26.3M | 0.68% | 16 |
|
|
2014
Q2 | $545K | Sell |
1,730
-8,904
| -84% | -$2.68M | 0.01% | 953 |
|
|
2014
Q1 | $3.25M | Buy |
10,634
+8,704
| +451% | +$2.76M | 0.08% | 314 |
|
|
2013
Q4 | $540K | Buy |
1,930
+200
| +12% | +$51.7K | 0.07% | 392 |
|
|
2013
Q3 | $417K | Sell |
1,730
-26,602
| -94% | -$5.95M | 0.01% | 1125 |
|
|
2013
Q2 | $6.1M | Buy |
+28,332
| New | +$6.05M | 0.15% | 160 |
|
Other funds holding BIIB
VCM
VPM
PDT Partners's BIIB Position: Q1 2026 in Review
PDT Partners held its Biogen (BIIB) position steady in Q1 2026 at 2,348 shares worth $430K. The position accounts for 0.03% of the portfolio, ranked #429.
PDT Partners first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $27M in Q3 2014. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- PDT Partners held 2,348 shares of Biogen worth $430K as of Q1 2026.
- PDT Partners left its Biogen share count unchanged in Q1 2026.
- Biogen made up 0.03% of PDT Partners's portfolio in Q1 2026, its #429 holding.
- PDT Partners first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- PDT Partners's Biogen position peaked at $27M in Q3 2014.
- 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.